Clinical trials: Immunity, Cellular
Meningococcal Infections
Regulation of Mucosal Immune Response to Systemic MenB Vaccine
Meningitis or septicaemia (blood poisoning) caused by group B meningococcal infection (MenB) is an important cause of death and disability in the UK. Prevention through vaccination therefore remains a key public health priority.
- Trial name
- NCT00774384
- Testing
- NZ MenB OMV vaccine (NZ98/254)
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Cytomegalovirus Infections
Cytomegalovirus Cell-Mediated Immunity
Cytomegalovirus (CMV) is an important cause of illness and occasional deaths in infants who catch the virus before they are born, in newborns, and in children and adults who have weak immune systems.
- Trial name
- NCT00815165
- Where
- 2 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Type 1
The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)
The Diabetes Prevention Trial of Type 1 (DPT-1) was a multicenter randomized, controlled clinical trial designed to determine whether it is possible to delay or prevent the clinical onset of type 1 diabetes through daily doses of…
- Trial name
- DPT-1 (NCT00004984)
- Testing
- Parenteral Insulin, Close Observation, Oral Insulin
- Where
- 15 sites in United States, Canada
- Volunteers
- 711 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Allergic Rhinitis, Asthma
Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen
The investigators propose the development of a range of nasal spray challenge models to study the way the nose can respond to different types of nasal challenge that elicit different forms of inflammation.
- Conditions
- Allergic Rhinitis, Asthma, Latent Tuberculosis
- Trial name
- NCT02090374
- Testing
- Poly ICLC, Poly I:C, R848
- Where
- United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Sars-CoV2, Innate Immunity
Immune Cells Phenotypes During COVID-19
The ongoing pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) has infected more than one hundred twenty million peoples worldwide one year after its onset with a case-fatality rate of almost 2%.
- Conditions
- Sars-CoV2, Innate Immunity, Immunization; Infection, Alveolar Lung Disease
- Trial name
- IMMUNO-COVID (NCT04816760)
- Testing
- Peripheral blood samples
- Where
- 2 sites in France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Institut Hospitalo-Universitaire Méditerranée Infection
Hepatitis B
New Methods to Measure the Immune Response to Hepatitis B Vaccine
Hepatitis B vaccine is a safe and effective vaccine used widely throughout the world. Because of this it is a useful vaccine in which to develop new methods for studying immune responses.
- Trial name
- NCT01821547
- Testing
- Hepatitis B vaccine
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Coronavirus, SARS-CoV-2 Infection
Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)
The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.
- Conditions
- Coronavirus, SARS-CoV-2 Infection, COVID-19
- Trial name
- NCT05633446
- Testing
- PepGNP-COVID19 (One vaccination), Water for injection (One vaccination), PepGNP-COVID19 (Two vaccinations)
- Where
- 2 sites in Philippines
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
Background: HIV stands for human immunodeficiency virus, which is the virus that causes AIDS. There is currently no licensed vaccine to prevent HIV infection.
- Trial name
- NCT03783130
- Testing
- VRC-HIVRGP096-00-VP, Alum Adjuvant
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005
The objectives of the study are to assess the immunogenicity and safety among three different lots of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.
- Trial name
- NCT00161811
- Testing
- Vero Cell-derived Influenza Vaccine, Egg cell-derived Influenza Vaccine
- Where
- 4 sites in Austria, Germany
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Human Papilloma Virus, Anal Dysplasia
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen…
- Conditions
- Human Papilloma Virus, Anal Dysplasia, HIV
- Trial name
- PROTECT (NCT06624839)
- Testing
- Human papillomavirus (HPV) vaccine, 9-valent
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Hepatitis B
Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders
Previous studies have shown that 5-10% of Hepatitis B Virus vaccine recipients produce none or to few antibodies after a standard immunization with 3 vaccines. These individuals are defined as non-responders.
- Trial name
- NCT01451801
- Testing
- Twinrix
- Where
- Denmark
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
COVID-19
Study on Antibody Persistence and Immune Memory of Inactivated COVID-19 Vaccine
The study describe 1 year durability of humoral and cellular immune responses in 150 individuals who received COVID-19 inactivated vaccine. all participants were recruited aged between 18 and 59 years old.
- Trial name
- NCT05072496
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Non-hodgkin Lymphoma,B Cell, Vaccination Failure
Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma
The specific immune response to SARS-CoV-2 includes a humoral response - specific IgM appearing 5 days after the onset of symptoms while IgG appears after 14 days - and a T lymphocyte component, with specific activated CD8 and…
- Trial name
- LYMPHO-CoVac (NCT05050461)
- Testing
- Immunological analyses
- Where
- 7 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Versailles Hospital
Immunity, Cellular
Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine
Immunization with the inactivated influenza vaccine with blood samples collected at 7 visits (baseline, day 7, 14, 28, 60, 90 and 180, fine needle aspiration (FNAs) from axillary lymph nodes at baseline, days, 4, 14, 28, 60 and…
- Trial name
- NCT03748524
- Testing
- Influenza Vaccine
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Bladder Cancer
Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and…
- Trial name
- NCT01198808
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Allogeneic Hematopoietic Stem Cell Transplantation
Non Randomized Comparative Study With Control
NK cells are lymphocytes who play a role in the control of viral infections , tumor and fœtal tolerance. They belong to innate immune cells but they have a link with adaptative immunity.
- Trial name
- Allo-NK-CMV (NCT03294824)
- Testing
- blood sample
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.
In order to investigate whether a germinal center response occurs following vaccine boost and to characterize it based on the type of vaccine received, we aim to analyze Spike and/or RBD-specific germinal center B cells within…
- Trial name
- LymphoBOOST (NCT05951920)
- Testing
- Lymph node aspiration / Blood sampling
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis, Cellular Immune Response
Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine
Patients with rheumatoid arthritis (RA) are prone to respiratory infections and therefore recommmended to receive vaccination against seasonal influenza.
- Trial name
- NCT01980836
- Testing
- Seasonal influenza vaccine
- Where
- Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Meningitis, Meningococcal Disease
Understanding the Immune Response to Two Different Meningitis Vaccines
The bacterium (germ) Neisseria meningitidis causes meningitis and blood poisoning. N meningitidis is classified into different serogroups (types), based on its outer polysaccharide (carbohydrate) capsule.
- Conditions
- Meningitis, Meningococcal Disease, Septicaemia
- Trial name
- NCT01593514
- Testing
- MenACWY-CRM conjugate vaccine (Menveo, Novartis), MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis), 1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Oxford
COVID-19 Respiratory Infection, COVID-19 Vaccine Adverse Reaction
A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine
This is a randomized, placebo-controlled, double-blinded phase I study, designed to evaluate the safety including reactogenicity and immunogenicity of this investigational DNA vaccine delivered intramuscularly by in vivo EP in…
- Trial name
- OpenCorona1 (NCT05685953)
- Testing
- DNA vaccine OC-007
- Where
- Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Matti Sällberg